FILINGS
| GSK 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2022-08-12 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2022-08-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-08-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-08-03 | 6-K | CURRENT REPORT OF FOREIGN ISSUER | View Document |
| 2022-08-03 | SC 13D/A | AMENDMENT TO FORM SC 13D | View Document |
| 2022-08-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-08-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-29 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-29 | 6-K | GSK BOARD CHANGE | View Document |
| 2022-07-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-27 | SC 13D | SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP | View Document |
| 2022-07-27 | 6-K | 2ND QUARTER RESULTS | View Document |
| 2022-07-22 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2022-07-22 | 6-K | BOARD AND COMMITTEE CHANGES | View Document |
| 2022-07-18 | 6-K | COMPLETION OF GSK SHARE CONSOLIDATION | View Document |
| 2022-07-18 | 6-K | HALEON DEMERGER COMPLETION AND SHARE CONSOLIDATION | View Document |
| 2022-07-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-08 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-08 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-08 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-08 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-08 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-06 | 6-K | RESULT OF GENERAL MEETING | View Document |
| 2022-07-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-05 | 6-K | GSK DISCLOSE DISCONTINUED OPERATIONS FROM Q2 2022 | View Document |
| 2022-07-05 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-05 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-07-01 | 6-K | GSK COMPLETES ACQUISITION OF SIERRA ONCOLOGY | View Document |
| 2022-06-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-06-28 | 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 2022-06-28 | 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 2022-06-28 | 6-K | GSK FILES SHINGRIX 18+ AT RISK INDICATION IN JAPAN | View Document |
| 2022-06-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-06-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-06-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-06-10 | 6-K | POSITIVE PHASE III DATA FOR GSK'S RSV OA VACCINE | View Document |
| 2022-06-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-06-07 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-06-06 | 6-K | US FDA APPROVAL OF PRIORIX | View Document |
| 2022-06-01 | 6-K | 6-K | View Document |
| 2022-06-01 | 6-K | DEMERGER UPDATE: PUBLICATION OF DOCUMENTS | View Document |
| 2022-06-01 | 6-K | DEMERGER UPDATE: SUBMISSION OF DOCUMENTS TO FCA | View Document |
| 2022-05-31 | 6-K | GSK TO ACQUIRE AFFINIVAX, INC. | View Document |
| 2022-05-31 | 6-K | FURTHER APPOINTMENTS TO DESIGNATE HALEON BOARD | View Document |
| 2022-05-27 | SD | SPECIALIZED DISCLOSURE | View Document |
| 2022-05-27 | 6-K | GSK CERVARIX TWO-DOSE SCHEDULE APPROVED BY NMPA | View Document |
| 2022-05-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-05-23 | 6-K | FORM 6-K | View Document |
| 2022-05-19 | 6-K | IAIN MACKAY - EXTERNAL APPOINTMENT | View Document |
| 2022-05-17 | 424B3 | 424B3 | View Document |
| 2022-05-17 | 424B3 | 424B3 | View Document |
| 2022-05-16 | 6-K | CHANGE OF NAME TO GSK PLC | View Document |
| 2022-05-13 | SC 13D/A | AMENDMENT TO FORM SC 13D | View Document |
| 2022-05-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-05-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-05-11 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2022-05-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-05-09 | 25-NSE | View Document | |
| 2022-05-06 | F-6EF | F-6 | View Document |
| 2022-05-04 | 6-K | RESULT OF AGM | View Document |
| 2022-05-04 | 6-K | DIRECTORATE CHANGE | View Document |
| 2022-05-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-05-02 | 25-NSE | View Document | |
| 2022-04-27 | 6-K | 1ST QUARTER RESULTS | View Document |
| 2022-04-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-19 | 6-K | DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY FDA | View Document |
| 2022-04-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-13 | DFAN14A | DFAN14A | View Document |
| 2022-04-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-13 | 6-K | GSK AGREES TO ACQUIRE SIERRA ONCOLOGY FOR $1.9BN | View Document |
| 2022-04-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-04-01 | 6-K | GSK - SEGMENT AND PRODUCT SALES REPORTING CHANGES | View Document |
| 2022-03-28 | 6-K | PUBLICATION OF 2022 AGM NOTICE | View Document |
| 2022-03-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-24 | 6-K | FDA UPDATE: CABENUVA ORAL LEAD-IN NOW OPTIONAL | View Document |
| 2022-03-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-23 | 6-K | ISSUANCE OF NOTES | View Document |
| 2022-03-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-15 | 6-K | APPOINTMENTS TO DESIGNATE HALEON BOARD | View Document |
| 2022-03-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-08 | 6-K | GSK ANNUAL REPORT 2021 ON FORM 20-F | View Document |
| 2022-03-08 | IRANNOTICE | IRANNOTICE | View Document |
| 2022-03-08 | 20-F | 20-F | View Document |
| 2022-03-04 | 6-K | GSK PUBLISHES ANNUAL REPORT 2021 | View Document |
| 2022-03-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-03-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-01 | 6-K | DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY EMA | View Document |
| 2022-02-28 | 6-K | FOMR 6-K | View Document |
| 2022-02-28 | 6-K | FORM 6-K | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
